drugset / Trial / NCT01702454

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine When Administered in Children Who Previously Participated in Study 115345

NCT01702454

Phase 3 Completed 470 enrolled GlaxoSmithKline
Non-randomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to assess the safety and immunogenicity of GSK Biologicals' investigational vaccine GSK2321138A in children who previously participated in study 115345 (FLU D-QIV-004 PRI) (NCT01439360).

Timeline

Start
2012-10-06
Primary completion
2013-05-06
Completion
2013-06-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluarix Quadrivalent Vaccine Intramuscular

Indications